SOCIETY PASS INCORPORATED UNDERWRITING AGREEMENTUnderwriting Agreement • February 14th, 2022 • Society Pass Incorporated. • Services-business services, nec • New York
Contract Type FiledFebruary 14th, 2022 Company Industry JurisdictionThe undersigned, Society Pass Incorporated, a Nevada corporation (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters;”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), (A)(i) an aggregate of 3,030,300 shares of common stock, (the “Firm Shares”) par value $0.0001 per share of the Company (“Common Stock”) and (ii) an aggregate of 3,030,300 common stock purchase warrants (“Firm Warrants”) and (B) at the election of the Representative,(i) up to an additional 454,545 shares of Common Stock (the “Option Shares” and collectively with the Firm Shares, the “Shares”) and/or (ii) up to an additional 454,545 common stock purchase warrants (the “Option Warrants” and collectively with the Firm Warrants, the “Warrants”).The shares of Common Stock issuable upon the exercise of the
SOCIETY PASS INCORPORATED UNDERWRITING AGREEMENTUnderwriting Agreement • January 14th, 2022 • Society Pass Incorporated. • Services-business services, nec • New York
Contract Type FiledJanuary 14th, 2022 Company Industry JurisdictionThe undersigned, Society Pass Incorporated, a Nevada corporation (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters;”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), (A)(i) an aggregate of ____________ shares of common stock, (the “Firm Shares”) par value $0.0001 per share of the Company (“Common Stock”) and (ii) an aggregate of [●] common stock purchase warrants (“Firm Warrants”) and (B) at the election of the Representative,(i) up to an additional _________ shares of Common Stock (the “Option Shares” and collectively with the Firm Shares, the “Shares”) and/or (ii) up to an additional ________ common stock purchase warrants (the “Option Warrants” and collectively with the Firm Warrants, the “Warrants”).The shares of Common Stock issuable upon the exercise of the
UNDERWRITING AGREEMENT between XENETIC BIOSCIENCES, INC.Underwriting Agreement • July 14th, 2016 • Xenetic Biosciences, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJuly 14th, 2016 Company Industry JurisdictionThe undersigned, Xenetic Biosciences, Inc., a corporation formed under the laws of the State of Nevada (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of Xenetic Biosciences, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with Ladenburg Thalmann & Co. Inc. (hereinafter referred to as “you” (including its correlatives) or the “Underwriter”) as follows:
COPSYNC, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • November 18th, 2015 • COPsync, Inc. • Computer communications equipment • New York
Contract Type FiledNovember 18th, 2015 Company Industry JurisdictionThe undersigned, COPsync, Inc., a Delaware corporation (the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, for whom Maxim Group LLC (“Maxim”) and Aegis Capital Corp. are acting as representatives (in such capacity, the “Representatives”), the “Underwriters” and each an “Underwriter”) to issue and sell to the Underwriters an aggregate of 3,028,572 Shares (“Shares”) of common stock, par value $0.0001 per share, of the Company (“Common Stock”), together with warrants to purchase an aggregate of 3,028,572 shares of Common Stock at an exercise price equal to $3.125 per share (each a “Warrant” and collectively, the “Warrants”). The offering and sale of securities contemplated by this Agreement is referred to herein as the “Offering.”